Barry J. Simon
Known title: DirectorCIK: 0001647994
Associated companies
Transaction History
| IBRX | ▼ Sell | Open Market | 25,000 | $197K | 6/24/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 23,033 | $165K | 6/4/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 75,000 | $901K | 2/24/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 165,000 | $1.7M | 2/23/2026 | View on chart |
| IBRX | ▲ Buy | Option Exercise | 15,243 | $0 | 2/22/2026 | View on chart |
| IBRX | ▼ Sell | Tax Withholding | 6,026 | $52K | 2/22/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 10,000 | $93K | 2/20/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 76,967 | $503K | 1/20/2026 | View on chart |
| IBRX | ▼ Sell | Open Market | 75,000 | $591K | 1/20/2026 | View on chart |
| IBRX | ▲ Buy | Option Exercise | 15,243 | $0 | 2/22/2025 | View on chart |
| IBRX | ▼ Sell | Tax Withholding | 5,453 | $19K | 2/22/2025 | View on chart |
| IBRX | ▲ Buy | Option Exercise | 110,020 | $220K | 1/22/2025 | View on chart |
| IBRX | ▲ Buy | Option Exercise | 57,200 | $0 | 1/31/2024 | View on chart |
| IBRX | ▼ Sell | Tax Withholding | 22,094 | $74K | 1/31/2024 | View on chart |
| IBRX | ▲ Buy | Option Exercise | 57,199 | $0 | 9/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News
ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News. ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.